To determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous IV insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)
TO determine whether there are fewer infections, days without a fever, days on antibiotics given for an infection and time to marrow engraftment are improved by intensive glucose management; and to determine whether there is evidence of a reduction in measures of inflammation in patients randomized to intensive glucose management and whether reduction of inflammation is associated with outcome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
11
Use of sliding scale insulin as per Appendix 1
Automated insulin delivery system
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Intensive Control of Glucose Effects on Mortality in Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Time frame: 100 days
Reduction of Infection
Time frame: About 100 days
Reduced Length of In-hospital Stay
Time frame: About 100 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.